Localized Immune Modulator Delivery for Endoderm Tissue Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immune modulators administered systemically for treating inflammatory diseases in tissues originating from the endoderm, such as the gastrointestinal tract, have limited efficacy and cause systemic side effects due to their mechanism of action, which involves blocking immune cell activation and cytokine secretion throughout the body.
Innovation Solution
Local, topical delivery of immune modulators to the gastrointestinal tract, using ingestible devices that release the modulators proximate to the intended site, achieving high concentrations and reducing systemic exposure, thereby targeting α4β7 integrin interactions and T cell recruitment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune modulators are administered systemically, then immune cell activation is blocked throughout the body, but systemic side effects occur and efficacy is limited
Solution Approach 1:
The patent applies local quality by transitioning from systemic administration to localized delivery of immune modulators directly to the gastrointestinal tract. This ensures the therapeutic agent acts preferentially on the target tissue (endoderm-derived organs) while minimizing exposure to other body systems, thereby reducing systemic side effects and improving therapeutic efficacy through concentrated local action.
Solution Approach 2:
The patent introduces an intermediary delivery system (ingestible device or topical application mechanism) that mediates between the immune modulator and the target tissue. This intermediary enables controlled local release of the therapeutic agent at the gastrointestinal tract, allowing precise targeting of α4β7 integrin interactions without requiring systemic distribution.
2Reliability
If immune modulators are administered systemically, then T-cell activation is blocked throughout the body, but the mean number of pro-inflammatory T cells in mesenteric lymph nodes is not significantly reduced
Solution Approach 1:
By delivering the immune modulator locally to the gastrointestinal tract, the patent creates a high concentration gradient at the target site (mesenteric lymph nodes and associated tissues) without requiring high systemic doses. This localized concentration strategy directly addresses the insufficiency of systemic administration in achieving adequate therapeutic levels at the specific target organs.
Solution Approach 2:
The patent changes the administration parameter from systemic distribution to localized delivery, fundamentally altering the concentration profile of the immune modulator. This parameter change results in high local concentrations at the gastrointestinal tract and draining lymph nodes, thereby significantly reducing pro-inflammatory T cells where needed, while avoiding the dilution effect of systemic administration.
3Reliability
If immune modulators are delivered topically to the gastrointestinal tract, then local concentrations are high and systemic exposure is reduced, but new delivery mechanisms are required
Solution Approach 1:
The patent employs self-service principles by designing ingestible devices that autonomously navigate to and release the immune modulator at the appropriate location in the gastrointestinal tract. The device utilizes the body's own physiological processes (peristalsis, pH gradients) for delivery and release, minimizing the need for complex external control systems while achieving effective local drug delivery.
Solution Approach 2:
The patent utilizes parameter changes in the gastrointestinal environment (such as pH transitions, enzymatic activity, or mechanical forces) to trigger controlled release of the immune modulator from the delivery device. This approach simplifies the device design by leveraging natural physiological parameters rather than requiring complex active control mechanisms, thereby achieving high local concentrations with reduced device complexity.
Data Source
AI summary
This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.